2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
119
CNS
71
Genitourinary
51
Gastrointestinal
42
Lymphoid
39
Gynecologic
26
Dermatologic
20
Other hematologic neoplasm
18
Myeloid
18
Head & Neck
12
Thoracic
10
Breast
10
Other solid neoplasm
9
Plasma cell
6
Endocrine
6
Classical hematology
2
Other
1
NET
1
Conditions
Neuroendocrine Tumors
531
Gastro-enteropancreatic neuroendocrine tumor
58
Carcinoid Tumor
58
Neoplasms
49
Carcinoma, Neuroendocrine
44
Pancreatic Neoplasms
36
Adenoma, Islet Cell
33
Neoplasm Metastasis
28
Pheochromocytoma
25
Colorectal Neoplasms
24
Paraganglioma
23
Stomach Neoplasms
21
Breast Neoplasms
21
Prostatic Neoplasms
20
Lung Neoplasms
20
Carcinoma, Hepatocellular
20
Sarcoma
19
Carcinoma
19
Thyroid Neoplasms
18
Gastrointestinal Neoplasms
18
Neuroblastoma
15
Cholangiocarcinoma
14
Carcinoma, Renal Cell
14
Small Cell Lung Carcinoma
13
Melanoma
13
Esophageal Neoplasms
13
Serotonin Syndrome
12
Colonic Neoplasms
12
Brain Neoplasms
11
Adenocarcinoma
11
Interventions
amino-acid, glucose, and electrolyte solution
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors, Primitive, Peripheral
×
NET
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled